Condition: Adenovirus · Primary Immune Deficiency Disorder · Sponsor: New York Medical College
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
This description comes directly from the study's public registry record.
Mitchell Cairo, MD · 914-594-2150 · mitchell_cairo@nymc.edu
Lauren Harrison, RN · 617-285-7844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Children's Hospital of Colorado | Aurora, Colorado, United States | Recruiting |
| University of Colorado Denver | Aurora, Colorado, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Not Yet Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Nationwide Children's Hosptial | Columbus, Ohio, United States | Recruiting |
| Children's Hospital of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Medical College of Wisconsin/Children's Hospital of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03266627